Cas:168293-13-8 3-O-Acetyl-16α-hydroxytrametenolic acid manufacturer & supplier

Chemical Name:3-O-Acetyl-16α-hydroxytrametenolic acid

CAS.NO:168293-13-8

Synonyms:Lanosta-8,24-dien-21-oic acid, 3-(acetyloxy)-16-hydroxy-, (3β,5ξ,16α)-;(3β,5ξ,16α)-3-Acetoxy-16-hydroxylanosta-8,24-dien-21-oic acid

Molecular Formula:C₃₂H₅₀O₅

Molecular Weight:514.736

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:606.9±55.0 °C at 760 mmHg

Density:1.1±0.1 g/cm3

Index of Refraction:1.546

PSA:

Exact Mass:514.365845

LogP:8.23

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like Lanosta-8,24-dien-21-oic acid, 3-(acetyloxy)-16-hydroxy-, (3β,5ξ,16α)- chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,(3β,5ξ,16α)-3-Acetoxy-16-hydroxylanosta-8,24-dien-21-oic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,(3β,5ξ,16α)-3-Acetoxy-16-hydroxylanosta-8,24-dien-21-oic acid Use and application,(3β,5ξ,16α)-3-Acetoxy-16-hydroxylanosta-8,24-dien-21-oic acid technical grade,usp/ep/jp grade.

Related News: He said the FDA made its decision by fiat, and had not asked its advisors to consider whether the drug’s ability to remove a type of brain plaques known as beta amyloid would improve outcomes for patients. 3-O-Acetyl-16α-hydroxytrametenolic acid manufacturer As Reuters reported last month, Lilly tapped the Washington D.C. law firm Covington & Burling LLP to investigate the alleged alterations, which the employees said were meant to downplay serious quality control problems at the plant producing the drugmaker’s COVID-19 antibody treatment. 3-O-Acetyl-16α-hydroxytrametenolic acid supplier Britons being brought from Wuhan to the UK are being placed in quarantine at Arrowe Park Hospital in the Wirral, northwest England, Raab said. 3-O-Acetyl-16α-hydroxytrametenolic acid vendor He said the FDA made its decision by fiat, and had not asked its advisors to consider whether the drug’s ability to remove a type of brain plaques known as beta amyloid would improve outcomes for patients. 3-O-Acetyl-16α-hydroxytrametenolic acid factory The on-body wear is similar to that of an insulin pump. Unlike insulin pump therapy, however, the investigational system is designed such that users enter only their body weight for the iLet to initialize therapy.